BriaCell Therapeutics Corp. Banner Image

BriaCell Therapeutics Corp.

  • Ticker BCTX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
BriaCell Therapeutics Corp. Logo Image
  • 11-50 Employees
  • Based in New York City, New York
BriaCell (TSXV: BCT) (OTCQB: BCTXF) is a clinical stage immuno-oncology focused biotechnology company developing the first off the shelf personalized immunotherapy for cancer. The company is conducting a Phase IIa clinical trial for its lead product candidate, Bria-IMT™, in advanced breast cancer along with the co-development of BriaDX™, its companion diagnostic. Additionally, there isMore an FDA approved combination study of Bria-IMT™ with pembrolizumab or ipilimumab for patients with advanced breast cancer previously treated with Bria-IMT™. Moreover, BriaCell is developing Bria-OTS™, the first “off the shelf” personalized treatment for advanced stage Breast Cancer. BriaCell's small molecule program consists of novel, selective protein kinase C delta inhibitors which have shown activity in pre-clinical models of several cancers and fibrotic diseases.
BriaCell Therapeutics Corp.

Most Recent Annual Report

BriaCell Therapeutics Corp.
MOST RECENT 2020 Annual Report

Older/Archived Annual Reports